Brain Canada Brain Canada
FR Donate

Our directory of funded grants

8 result(s) found

‘Best in Class’ Platform for Blood Brain Barrier Delivery of Therapeutics

Project Overview

The blood-brain barrier (BBB) is a tightly woven layer of vascular cells in the brain that prevents harmful molecules from the circulation, viruses and toxins, from entering the brain. To allow entry of nutrients into the brain, the BBB employs molecular transporters that shuttle nutrients back and …

See researchers on this project
Principal Investigator:
  • Danica Stanimirovic, National Research Council of Canada
Team Members:
  • Reinhard Gabathuler, BiOasis Technologies Inc.
  • Brigitte Guérin, Université de Sherbrooke
  • Roger Lecomte, Université de Sherbrooke
  • David Fortin, Université de Sherbrooke

A Patient-Derived hiPSC Neuronal Platform for Drug Discovery in Parkinson’s Disease and Amyotrophic Lateral Sclerosis

Project Overview

Parkinson’s Disease (PD) and Amyotrophic Lateral Sclerosis (ALS) are two of the most common and devastating neurodegenerative diseases, affecting more than 2% of the population over the age of 65. However, a major hindrance in developing therapies for disorders of the brain has been limited access…

See researchers on this project
Principal Investigator:
  • Edward Fon, McGill University
Team Members:
  • Guy Rouleau, Montreal Neurological Hospital and Institute
  • Nicolas Dupré, CRCHUQ-Enfant-Jesus, University Laval
  • Tom Pfeifer, Centre for Drug Research and Development
  • Neil Cashman, University of British Columbia
  • Thomas Durcan, Montreal Neurological Institute and Hospital, McGill University
  • Philippe Seguela, McGill University

Cyto-iGluSnFR: A glutamate biosensor platform for brain diseases

Project Overview

In the human brain and retina, the chemical glutamate is a very important messenger that carries information from one neuron to another. The levels of glutamate transmitted between neurons must be tightly controlled: too high and neurons die, too low and information is not communicated properly. In …

See researchers on this project
Principal Investigator:
  • Don van Meyel, Research Institute of the McGill University Health Centre
Team Members:
  • Keith Murai, Research Institute of the McGill University Health Centre
  • Adriana Di Polo, CHUM Research Centre, University of Montréal
  • Tim Murphy, University of British Columbia

Drug Delivery across the Human Blood-Brain Barrier

Project Overview

Toxic amyloid proteins are known to be a significant contributing factor in the development of Alzheimer’s disease. Abnormal clusters of protein fragments build up between nerve cells in the brainleading to impaired memory. The most important therapies in development currently are biologics, antib…

See researchers on this project
Principal Investigator:
  • Nathan Yoganathan, KalGene Pharmaceuticals Inc
Team Members:
  • Louis Collins, McGill University
  • Jean-Paul Soucy, McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University
  • Danica Stanimirovic, National Research Council of Canada
  • Balu Chakravarthy, Carleton University
  • Pedro Rosa-Neto, Douglas Mental Health University Institute

Human MiniPromoters for Restricted Expression of Ocular Gene Therapy

Project Overview

The purpose of this project is to develop promoters. Promoters are pieces of DNA, which act as switches to turn genes on and off. Such promoters are important tools for drug companies working on developing gene-based therapies; known as gene therapies. These are a type of biological therapy, somewha…

See researchers on this project
Principal Investigator:
  • Elizabeth Simpson, University of British Columbia
Team Members:
  • Adriana Di Polo, CHUM Research Centre, University of Montréal